Skip to main navigation

About Us
Programs
Join Us
Investors
Contact Us

Press Releases

Investors & Media

Overview
Press Releases
Events & Presentations
Financials
Stock Information
Analyst Coverage
Governance
Contact & FAQs

Stockholder Tools

Print Page
RSS Feeds
Email Alerts
Contact Us

Year

November 20, 2023

Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension

November 13, 2023

Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights

August 14, 2023

Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights

July 11, 2023

Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors

June 1, 2023

Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference

May 22, 2023

Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International Conference

May 15, 2023

Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights

March 29, 2023

Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights

March 2, 2023

Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference

January 23, 2023

Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 28

Investors & Media

Overview
Press Releases
Events & Presentations
Financials
Stock Information
Analyst Coverage
Governance
Contact & FAQs

Stockholder Tools

Print Page
RSS Feeds
Email Alerts
Contact Us

About Us
Programs
Join Us
Investors
Contact Us

© 2023 Aerovate Therapeutics, Inc. All Rights Reserved. | Privacy Policy | Terms of Use